OJRad  Vol.3 No.3 , September 2013
Comparison Study on Different Quantification Methods of Diffuse Myocardial Fibrosis of Dilated Cardiomyopathy Using Myocardial T1 Value
ABSTRACT

Purpose: The purpose is to compare several quantification methods and clarify which quantification method is reliable to estimate diffuse myocardial fibrosis with cardiac MRI in patients with dilated cardiomyopathy (DCM) using myocardial T1 value. Methods and Results: Delayed enhancement imaging was performed in 52 patients with DCM and 10 control subjects to identify fibrosis using an inversion time scout sequence. The mean contrast-enhanced myocardial (M) T1 values of the pre and post contrast-enhanced myocardial and left ventricular lumen (L) of control and dilated cardiomyopathy cases were compared. The calculated post M T1 value, pre M T1 value-post M T1 value, and (pre M TI value-post M T1 value)/(pre L T1 value-post L T1 value) were significantly different between the patient group and the control group (344.5 ± 31.6 vs. 390.4 ± 19.3 msec, 239.9 ± 64.2 msec vs. 134.0 ± 28.9 msec, and 0.50 ± 0.11 vs. 0.30 ± 0.60, respectively). (Pre M T1 value-post M T1 value)/(pre L T1 value-post L T1 value) was significantly the most related to the left ventricular ejection fraction (r = 0.66, p < 0.0001). Conclusion: (Pre M T1 value-post M T1 value)/(pre L T1 value-post L T1 value) was the most reliable quantification method to estimate the severity of DCM.


Cite this paper
T. Hayashida, E. Sueyoshi, H. Nagayama, I. Sakamoto and M. Uetani, "Comparison Study on Different Quantification Methods of Diffuse Myocardial Fibrosis of Dilated Cardiomyopathy Using Myocardial T1 Value," Open Journal of Radiology, Vol. 3 No. 3, 2013, pp. 117-123. doi: 10.4236/ojrad.2013.33019.
References
[1]   L. Iles, H. Pfluger, A. Phrommintikul, J. Cherayath, P. Aksit, S. N. Gupta, D. M. Kaye and A. J. Taylor, “Eva luation of Diffuse Myocardial Fibrosis in Heart Failure with Cardiac Magnetic Resonance Contrast-Enhanced T1 Mapping,” Journal of the American College of Cardi ology, Vol. 52, No. 19, 2008, pp. 1574-1580. doi:10.1016/j.jacc.2008.06.049

[2]   T. M. Koelling, R. S. Chen, R. N. Lubwama, G. J. L’Italien and K. A. Eagle, “The Expanding National Burden of Heart Failure in the United States: The Influence of Heart Failure in Women,” American Heart Journal, Vol. 147, No. 1, 2004, pp. 74-78. doi:10.1016/j.ahj.2003.07.021

[3]   D. L. Mann, “Mechanisms and Models in Heart Failure: A Combinatorial Approach,” Circulation, Vol. 100, 1999, pp. 999-1008. doi:10.1161/01.CIR.100.9.999

[4]   T. F. Ismail, S. K. Prasad and D. J. Pennell, “Prognostic Importance of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiomyopathy,” Heart, Vol. 98, No. 6, 2012, pp. 438-442. doi:10.1136/heartjnl-2011-300814

[5]   E. Sueyoshi, I. Sakamoto and M. Uetani, “Contrast-En hanced Myocardial Inversion Time at the Null Point for Detection of Left Ventricular Myocardial Fibrosis in Patients with Dilated and Hypertrophic Cardiomyopathy: A Pilot Study,” American Journal of Roentgenology, Vol. 194, No. 4, 2010, pp. W293-W298. doi:10.2214/AJR.09.3414

[6]   P. Richardson, W. McKenna, M. Bristow, B. Maisch, B. Mautner, J. O’Connell, E. Olsen, G. Thiene, J. Goodwin, I. Gyarfas, I. Martin and P. Nordet, “Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies,” Circulation, Vol. 93, 1996, pp. 841-842.
doi:10.1161/01.CIR.93.5.841

[7]   P. Sparrow, D. R. Messroghli, S. Reid, J. P. Ridgway, G. Bainbridge and M. U. Sivananthan, “Myocardial T1 Map ping for Detection of Left Ventricular Myocardial Fibro sis in Chronic Aortic Regurgitation: Pilot Study,” Ameri can Journal of Roentgenology, Vol. 187, No. 6, 2006, pp. W630-W635.
doi:10.2214/AJR.05.1264

[8]   D. R. Messroghli, S. Plein, D. M. Higgins, K. Walters, T. R. Jones and J. P. Ridgway, “Human Myocardium: Sin gle-Breath-Hold MR T1 Mapping with High Spatial Re solution—Reproducibility Study,” Radiology, Vol. 238, No. 3, 2006, pp. 1004-1012. doi:10.1148/radiol.2382041903

[9]   K. H. Zou, K. Tuncali and S. G. Silverman, “Correlation and Simple Linear Regression,” Radiology, Vol. 227, No. 3, 2003, pp. 617-622. doi:10.1148/radiol.2273011499

[10]   R. J. Kim, E. Wu, A. Rafael, E. L. Chen, M. A. Parker, O. Simonetti, F. J. Klocke, R. O. Bonow and R. M. Judd, “The Use of Contrast-Enhanced Magnetic Resonance Imaging to Identify Reversible Myocardial Dysfunction,” The New England Journal of Medicine, Vol. 343, No. 20, 2000, pp. 1445-1453. doi:10.1056/NEJM200011163432003

[11]   R. G. Assomull, S. K. Prasad, J. Lyne, G. Smith, E. D. Burman, M. Khan and M. N. Sheppard, P. A. Poole Wilson and D. J. Pennell, “Cardiovascular Magnetic Resonance, Fibrosis, and Prognosiin Dilated Cardio myopathy,” Journal of the American College of Cardiology, Vol. 48, No. 10, 2006, pp. 1977-1985. doi:10.1016/j.jacc.2006.07.049

[12]   D. Bello, D. S. Fieno, R. J. Kim, F. S. Pereles, R. Pass man, G. Song, A. H. Kadish and J. J. Goldberger, “Infarct Morphology Identifies Patients with Substrate for Sus tained Ventricular Tachycardia,” Journal of the American College of Cardiology, Vol. 45, No. 7, 2005, pp. 1104-1108. doi:10.1016/j.jacc.2004.12.057

[13]   D. Bello, D. J. Shah, G. M. Farah, S. Di Luzio, M. Parker, M. R. Johnson, W. G. Cotts, F. J. Klocke, R. O. Bonow, R. M. Judd, M. Gheorghiade and R. J. Kim, “Gadolinium Cardiovascular Magnetic Resonance Predicts Reversible Myocardial Dysfunction and Remodeling in Patients with Heart Failure Undergoing Betablocker Therapy,” Circulation, Vol. 108, 2003, pp. 1945-1953.
doi:10.1161/01.CIR.0000095029.57483.60

[14]   A. M. Huber, S. O. Schoenberg, C. Hayes, B. Spannagl, M. G. Engelmann, W. M. Franz and M. F. Reiser, “Phasesensitive Inversion-Recovery MR Imaging in the Detection of Myocardial Infarction,” Radiology, Vol. 237, No. 3, 2005, pp. 854-860. doi:10.1148/radiol.2373041483

[15]   J. N. Oshinski, Z. Yang, J. R. Jones, J. F. Mata and B. A. French, “Imaging Time after Gd-DTPA Injection is Critical in Using Delayed Enhancement to Determine Infarct Size Accurately with Magnetic Resonance Imaging,” Circulation, Vol. 104, 2001, pp. 2838-2842. doi:10.1161/hc4801.100351

[16]   C. Klein, S. G. Nekolla, F. M. Bengel, M. Momose, A. Sammer, F. Haas, B. Schnackenburg, W. Delius, H. Mudra, D. Wolfram and M. Schwaiger, “Assessment of Myocardial Viability with Contrast Enhanced Magnetic Resonance Imaging: Comparison with Positron Emission Tomography,” Circulation, Vol. 105, 2002, pp. 62-167. doi:10.1161/hc0202.102123

[17]   A. K. Kono, N. Yamada, M. Higashi, S. Kanzaki, H. Hashimura, Y. Morita, T. Sakuma, T. Noguchi, H. Naito and K. Sugimura, “Dynamic Late Gadolinium Enhance ment Simply Quantified Using Myocardium to Lumen Signal Ratio: Normal Range of Ratio and Diffuse Ab normal Enhancement of Cardiac Amyloidosis,” Journal of Magnetic Resonance Imaging, Vol. 34, No. 1, 2011, pp. 50-55. doi:10.1002/jmri.22602

[18]   J. J. Bax, D. Poldermans, A. Elhendy, J. H. Cornel, E. Boersma, R. Rambaldi, J. R. Roelandt and P. M. Fioretti, “Improvement of Left Ventricular Ejection Fraction, Heart Failure Symptoms and Prognosis after Revascu larization in Patients with Chronic Coronary Artery Dis ease and Viable Myocardium Detected by Dobutamine Stress Echocardiography,” Journal of the American Col lege of Cardiology, Vol. 34, No. 1, 1999, pp. 163-169. doi:10.1016/S0735-1097(99)00157-6

[19]   F. Cacciapuoti, “Are Clinical Heart Failure and Ejection Fraction Always Connected?” Open Heart Failure Journal, Vol. 3, 2010, pp. 1-8.

[20]   I. Nishi, T. Noguchi, Y. Iwanaga, S. Furuichi, N. Aihara, H. Takaki and Y. Goto, “Effects of Exercise Training in Patients with Chronic Heart Failure and Advanced Left Ventricular Systolic Dysfunction Receiving β-Blockers,” Circulation Journal, Vol. 75, No. 7, 2011, pp. 1649-1655. doi:10.1253/circj.CJ-10-0899

 
 
Top